SummaryRMgm-154
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 16796674 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA 2.34 |
Other information parent line | P. berghei ANKA 2.34 is a cloned, gametocyte producer line of the ANKA strain (PubMed: PMID: 15137943). |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | I. Siden-Kiamos; O. Billker |
Name Group/Department | Division of Cell and Molecular Biology |
Name Institute | Imperial College London |
City | London |
Country | United Kingdom |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-154 |
Principal name | cdpk3- |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Normal numbers of ookinetes are produced. These ookinetes have a (light microscope) morphology that is comparable to wild type ookinetes. Ookinetes show a strong reduction (98%) in the formation of oocysts in A. stephensi mosquitoes. Ookinetes fail to associate with the midgut epithelium. Ookinetes showed a strongly reduced ability to glide productively. |
Oocyst | Ookinetes show a strong reduction (98%) in the formation of oocysts in A. stephensi mosquitoes. Injection of in vitro cultured, mature ookinetes into the hemocoel and thereby by-passing the midgut wall resulted in normal development of oocysts and infectious sporozoites. |
Sporozoite | Not different from wild type |
Liver stage | Not different from wild type |
Additional remarks phenotype | Mutant/mutation Disruption of the P. falciparum ortholog has been attempted (Solyakov et al., 2011, Nat Commun, 2:565). |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0408200 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0310100 | ||||||||||||||||||||||||
Gene product | calcium-dependent protein kinase 3 | ||||||||||||||||||||||||
Gene product: Alternative name | CDPK3 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | KpnI/BamHI | ||||||||||||||||||||||||
Partial or complete disruption of the gene | Partial | ||||||||||||||||||||||||
Additional remarks partial/complete disruption |
5' targetting region: a 608 bp fragment comprising 5′ upstream sequence followed by the first 543 bp of exon1 of cdpk3 3' targetting region: A 686 bp fragment comprising the last two exons and 3′ flanking region of pbcdpk3 No additional information on primer sequences is available. | ||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | No additional information on primer sequences used for the replacement construct is provided in the paper! | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |